Chronic graft-vs-host disease in 2016: a major challenge and an opportunity

Abstract

Despite major advances in the treatment of hematological diseases over the last decades, allogeneic hematopoietic stem cell transplantation (alloHSCT) still remains the only curative option for many of them. According to the recent survey of the European Society of Blood and Marrow Transplantation (EBMT), nearly 15 000 alloHSCT are currently performed each year across Europe and EBMTaffiliated countries (1).

Extracted Key Phrases

Cite this paper

@inproceedings{Pulani2016ChronicGD, title={Chronic graft-vs-host disease in 2016: a major challenge and an opportunity}, author={Dra{\vz}en Pulani{\'c} and Lana Desnica and Radovan Vrhovac and Damir Nemet and Daniel Wolff and Hildegard T. Greinix and Steven Z Pavletic}, booktitle={Croatian medical journal}, year={2016} }